SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

Autor: S, Barnette M, B, Christensen S, M, Essayan D, M, Grous, U, Prabhakar, A, Rush J, A, Kagey-Sobotka, J, Torphy T

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; January 1998, Vol. 284 Issue: 1 p420-6, 7p

Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Autor: C, Underwood D, S, Bochnowicz, R, Osborn R, J, Kotzer C, A, Luttmann M, W, Hay D, D, Gorycki P, B, Christensen S, J, Torphy T

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; December 1998, Vol. 287 Issue: 3 p988-95, 8p

The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig.

Autor: C, Underwood D, K, Matthews J, R, Osborn R, S, Bochnowicz, J, Torphy T

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; January 1997, Vol. 280 Issue: 1 p210-9, 10p